Expert Review of Gastroenterology & Hepatology最新文献_第2页

Unraveling the link: diagnosing metabolic dysfunction-associated steatotic liver disease in the context of decompensated cirrhosis.

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-02-18 DOI: 10.1080/17474124.2025.2469267

Mohamed El-Kassas, Marwa Khalaf Hassan, Khalid Al-Naamani

引用次数: 0

Determining the value of endoscopic retrograde cholangiopancreatography in the management of patients with acute pancreatitis and related complications.

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-02-17 DOI: 10.1080/17474124.2025.2464057

Sujani Yadlapati, Aditya Gutta, Evan L Fogel

引用次数: 0

Migration of surgical clips into the biliary tree - the potential for cholangioscopy.

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-02-15 DOI: 10.1080/17474124.2025.2467309

Carlo Ciccioli, Aurelio Mauro, Stefano Mazza, Davide Scalvini, Marco Bardone, Andrea Anderloni

引用次数: 0

Onset of pouchitis after colectomy for ulcerative colitis: reducing the risk. 溃疡性结肠炎结肠切除术后出现肠袋炎：降低风险。

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-02-06 DOI: 10.1080/17474124.2025.2464058

Edward L Barnes

{"title":"Onset of pouchitis after colectomy for ulcerative colitis: reducing the risk.","authors":"Edward L Barnes","doi":"10.1080/17474124.2025.2464058","DOIUrl":"10.1080/17474124.2025.2464058","url":null,"abstract":"Introduction: Pouchitis remains the most common complication after ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (IPAA). Despite the burden of pouchitis, our ability to recognize the patients at greatest risk for pouchitis and to offer early intervention for the prevention or early treatment is limited.Areas covered: In this review, we will discuss the diagnostic categories of pouchitis, as well as the common approaches to treatment. We will then discuss gaps in research and clinical care. These include opportunities to improve our understanding of the risk factors associated with the development of pouchitis as well as the role that primary and secondary prevention may play in the management of patients after IPAA to prevent pouchitis. We will then discuss future research goals to decrease the burden of pouchitis.Expert opinion: Although the burden of pouchitis is well recognized, we have an opportunity to improve our methods of risk stratification to offer early intervention to those patients at the greatest risk for developing pouchitis. Understanding which preventive therapies, in which populations, and under which treatment settings offer the most benefit will be critical issues to address in the near future to improve care of patients after IPAA for UC.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"1-8"},"PeriodicalIF":3.8,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143188151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comprehensive care of ulcerative colitis: new treatment strategies.

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-01-26 DOI: 10.1080/17474124.2025.2457451

Thanaboon Chaemsupaphan, Arteen Arzivian, Rupert W Leong

{"title":"Comprehensive care of ulcerative colitis: new treatment strategies.","authors":"Thanaboon Chaemsupaphan, Arteen Arzivian, Rupert W Leong","doi":"10.1080/17474124.2025.2457451","DOIUrl":"https://doi.org/10.1080/17474124.2025.2457451","url":null,"abstract":"Introduction: Ulcerative colitis is a chronic inflammatory condition of the colon driven by aberrant immune activation. Although advanced medical therapies form the cornerstone of ulcerative colitis management, unmet needs include failure to induce and sustain remission in a substantial proportion of patients and in managing acute severe ulcerative colitis. We review new treatment strategies that might improve patient outcomes in the management of moderate-to-severe ulcerative colitis.Areas covered: A literature search was conducted using the PubMed database, including studies published from inception to October 2024, selected for their relevance. Recognizing current limitations, this article reviews strategies to improve treatment outcomes in ulcerative colitis using advanced therapies. These approaches include early treatment initiation, dose optimization, positioning newer agents as first-line therapies, combination therapy, targeting novel therapeutic endpoints, and the management of acute severe ulcerative colitis.Expert opinion: The strategies discussed may contribute to establishing new standards of care aimed at achieving long-term remission and enhancing patient outcomes. Personalized therapy, which tailors treatment based on individual disease characteristics and risk factors, is anticipated to become a critical aspect of delivering more effective care in the future.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An evidence-based update on the diagnosis and management of irritable bowel syndrome. 肠易激综合征诊断和治疗的循证最新进展。

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-01-21 DOI: 10.1080/17474124.2025.2455586

Christopher J Black, Alexander C Ford

{"title":"An evidence-based update on the diagnosis and management of irritable bowel syndrome.","authors":"Christopher J Black, Alexander C Ford","doi":"10.1080/17474124.2025.2455586","DOIUrl":"https://doi.org/10.1080/17474124.2025.2455586","url":null,"abstract":"Introduction: Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction affecting 5% of the population. The cardinal symptoms are abdominal pain and altered stool form or frequency.Areas covered: Diagnosis and management of IBS. We searched the literature for diagnostic accuracy studies, randomized controlled trials, and meta-analyses. A positive diagnosis of IBS, alongside testing to exclude celiac disease, is recommended. Exhaustive investigation has a low yield. Patients should be offered traditional dietary advice. If response is incomplete, specialist dietetic guidance should be considered. Probiotics may be beneficial, but quality of evidence is poor. First-line treatment of constipation is with laxatives, with secretagogues used where these are ineffective. Anti-diarrheal drugs should be used first-line for diarrhea, with second-line drugs including 5-hydroxytryptamine-3 antagonists, eluxadoline, or rifaximin, where available. First-line treatment of abdominal pain should be with antispasmodics, with gut-brain neuromodulators prescribed second-line. Low-dose tricyclic antidepressants, such as amitriptyline, are preferred. Brain-gut behavioral therapies are effective and have evidence for efficacy in patients refractory to standard therapies.Expert opinion: Despite substantial advances, there remains scope for improvement in terms of both the diagnosis and management of IBS. Reinforcement of positive diagnostic strategies for the condition and novel treatment paradigms are required.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"1-16"},"PeriodicalIF":3.8,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of disease-related abdominal abscesses in Crohn's disease.

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-01-01 Epub Date: 2025-02-02 DOI: 10.1080/17474124.2025.2462220

Ruiqing Liu, Jana G Hashash, Luca Stocchi

{"title":"Management of disease-related abdominal abscesses in Crohn's disease.","authors":"Ruiqing Liu, Jana G Hashash, Luca Stocchi","doi":"10.1080/17474124.2025.2462220","DOIUrl":"10.1080/17474124.2025.2462220","url":null,"abstract":"Introduction: Crohn's disease (CD)-related abdominal abscesses require tailored management strategies taking into consideration the variability in abscess size, location, and underlying CD activity.Areas covered: This review discusses current approaches to CD-related abscesses. Literature review was performed through the PubMed and Medline databases to identify studies pertinent to the wide-ranging focus of this review.Expert opinion: Early, individualized treatment combining medical and surgical strategies is crucial for optimizing outcomes in patients with CD-related abdominal abscesses. Antibiotics are effective for smaller abscesses in hemodynamically stable patients; however, recurrence is common, necessitating close monitoring. Percutaneous drainage (PD) provides a less invasive alternative to surgery, offering high initial success rates but variable long-term results, as many patients ultimately need a definitive surgical intervention. For larger or complex abscesses, surgery may be necessary to address both the abscess and underlying CD. Despite its invasiveness, surgery is associated with high success rates and reduced recurrence risk. Biologic therapies, particularly anti-TNF agents, have shown promise in managing CD-associated abscesses, and can reduce abscess recurrence risk without surgery. While biologics may help delay or avoid surgery in select patients, interdisciplinary collaboration is essential to mitigate the risks associated with immunosuppression in the presence of intra-abdominal infections.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"131-144"},"PeriodicalIF":3.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143070771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interventions to improve bowel cleansing in colonoscopy. 改善结肠镜检查中肠道清洁的干预措施。

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-01-01 Epub Date: 2025-01-08 DOI: 10.1080/17474124.2025.2450699

Antonio Z Gimeno-García, Davinia Sacramento-Luis, Rashika Ashok-Bhagchandani, David Nicolás-Pérez, Manuel Hernández-Guerra

{"title":"Interventions to improve bowel cleansing in colonoscopy.","authors":"Antonio Z Gimeno-García, Davinia Sacramento-Luis, Rashika Ashok-Bhagchandani, David Nicolás-Pérez, Manuel Hernández-Guerra","doi":"10.1080/17474124.2025.2450699","DOIUrl":"10.1080/17474124.2025.2450699","url":null,"abstract":"Introduction: Suboptimal bowel preparation adversely affects colonoscopy quality, increases healthcare costs, and prolongs waiting time. The primary contributing factors include poor tolerance to the preparation solutions, noncompliance with prescribed instructions, and suboptimal efficacy of the bowel cleansing solution itself.Areas covered: This review examined the predictive factors associated with suboptimal bowel preparation and discussed interventions aimed at improving bowel cleansing. It also provides evidence-based practical algorithms supplemented by insights from our own clinical experience. Relevant topics were reviewed using resources from the PubMed database.Expert opinion: Although current bowel preparation protocols are effective for the majority of patients, a significant proportion still present challenges for optimal preparation. These patients may benefit from personalized strategies tailored to the specific causes of preparation failure. Conducting a thorough interview is crucial for identifying the reasons for failure, particularly in patients who have previously experienced suboptimal preparation during colonoscopy. In colonoscopy-naïve patients, it is essential to assess the risk of suboptimal preparation. In both cases, interventions should be customized to either address the identified causes in the former group or employ preventive strategies to reduce the likelihood of failure in the latter.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"39-51"},"PeriodicalIF":3.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel nutrition strategies in gastric and esophageal cancer.

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-01-01 Epub Date: 2025-01-30 DOI: 10.1080/17474124.2025.2457444

Ellen Boyle, Jessie A Elliott

{"title":"Novel nutrition strategies in gastric and esophageal cancer.","authors":"Ellen Boyle, Jessie A Elliott","doi":"10.1080/17474124.2025.2457444","DOIUrl":"10.1080/17474124.2025.2457444","url":null,"abstract":"Introduction: Advances in treatment strategies for gastric and esophageal cancer have led to improved long-term outcomes, however the local and systemic effects of the primary tumor, neoadjuvant therapies and surgery, result in specific nutritional challenges. Comprehensive nutritional evaluation and support represents a core component of multidisciplinary holistic care for this patient population.Areas covered: We provide a detailed overview of nutritional challenges in gastric and esophageal cancer, with a focus on malignant obstruction, preoperative optimization and survivorship. We discuss current management strategies and evidence base, and describe future therapeutic targets.Expert opinion: Data to support the optimal management of malignant dysphagia and obstruction, particularly regarding patient reported outcomes, is currently lacking. The advantages of nutritional optimization in the pre- and immediate postoperative phase are well described, but further research is needed to inform optimal personalised strategies. Emerging data regarding the physiologic regulation of appetite and body weight have provided key insights and informed the development of novel therapeutic targets to improve nutritional status among patients undergoing treatment for oesophageal and gastric cancer.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"89-104"},"PeriodicalIF":3.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dupilumab is efficacious for eosinophilic esophagitis irrespective of prior swallowed budesonide or fluticasone, or prior treatments used alongside swallowed topical corticosteroids: results from the phase 3, randomized, placebo-controlled, LIBERTY EoE TREET trial.

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-01-01 Epub Date: 2025-02-05 DOI: 10.1080/17474124.2025.2461516

Albert J Bredenoord, Evan S Dellon, Christoph Schlag, Antonella Cianferoni, Changming Xia, Tiffany Pela, Sandy Durrani, Amr Radwan, Juby A Jacob-Nara

{"title":"Dupilumab is efficacious for eosinophilic esophagitis irrespective of prior swallowed budesonide or fluticasone, or prior treatments used alongside swallowed topical corticosteroids: results from the phase 3, randomized, placebo-controlled, LIBERTY EoE TREET trial.","authors":"Albert J Bredenoord, Evan S Dellon, Christoph Schlag, Antonella Cianferoni, Changming Xia, Tiffany Pela, Sandy Durrani, Amr Radwan, Juby A Jacob-Nara","doi":"10.1080/17474124.2025.2461516","DOIUrl":"10.1080/17474124.2025.2461516","url":null,"abstract":"Background: Standard treatments for eosinophilic esophagitis (EoE) may present adherence, tolerance, and efficacy challenges. Dupilumab 300 mg weekly is approved for the treatment of EoE in patients ≥ 1 year old, weighing ≥ 15 kg. This analysis aimed to evaluate dupilumab efficacy in patients from the LIBERTY EoE TREET trial (NCT03633617), with prior history of different EoE interventions.Research design and methods: This analysis included patients from Parts B/B - C of LIBERTY EoE TREET. Dupilumab efficacy was analyzed according to prior swallowed budesonide or fluticasone use and in those patients with previously trialed food elimination diet, esophageal dilation, or baseline proton pump inhibitor use, as stratified by prior swallowed topical corticosteroid (STC) use or STC inadequate response/intolerance/contraindication.Results: Dupilumab improved the proportion of patients achieving peak intraepithelial eosinophil count ≤ 6 eosinophils/high-power field, absolute change in Dysphagia Symptom Questionnaire score, and other histologic, symptomatic, and endoscopic endpoints vs. placebo at Week (W) 24, irrespective of prior swallowed budesonide/fluticasone use. Improvements were maintained at W52. Similar results were observed across the other subgroups.Conclusion: Dupilumab was efficacious in patients with EoE irrespective of prior treatments/interventions.Clinical trial registration: www.clinicaltrials.gov identifier is NCT03633617.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"197-209"},"PeriodicalIF":3.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0